Deutsche Bank Comments On CELG Guidance Reiteration

Celgene Corporation CELG reiterated its '15 guidance of $8B in total revs & $8 in EPS, Deutsche Bank reports. “The company sees $6-6.5B revs coming from hematology business,” Deutsche Bank writes. “Revlimid will contribute towards 70%-80% of hematology sales. Abraxane '15 sales are expected in the range of $1-1.2B. The remaining revs are expected to come from Apremilast sales. “Celgene expects to achieve the total rev guidance even if Apremilast does not launch as it sees enough buffers in the existing product portfolio to reach to guidance levels.” Celgene Corporation closed Monday at $59.78.